Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers
MORRISVILLE, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, is pulsing a series of 2021 Health Trends – Speed and Scale in the Great Disruption, offering new insights into the key drivers of growth for the life sciences and health sectors in the year ahead. Syneos Health is now providing its annual predictions in a staged release format, detailing the most significant and actionable trends driving biopharmaceutical growth for the next decade.
“We enter 2021 energized and humbled by the impact of COVID-19 on the world and the healthcare industry, and in awe of the overwhelming response to this crisis,” said Leigh Householder, Managing Director, Omnichannel Strategy and Trends Editor for Syneos Health. “For a decade, Trends has served as an accelerant to the ongoing ideas, priorities and focus to improving health. We do not see that whiplash of change slowing, and the investments being made to meet the demands of a new approach to health will continue to spark developments.”
As Syneos Health experts continue to monitor and identify trends anticipated to reshape the biopharmaceutical landscape and accelerate growth and impact, four overarching themes emerged as game-changers for patients, healthcare providers, biopharmaceutical companies, and other industry stakeholders:
2021 Health Trends – Speed and Scale in the Great Disruption is being pulsed weekly to provide more agile, real-time perspectives, and is available at trends.health.
“At Syneos Health, we are innovating with and for our clients, and driving change in how we deliver integrated clinical and commercial solutions,” added Householder. “Given COVID-19’s disruption, we remain grounded in providing the most relevant solutions, and high-value content, to our customers, patients, vendors and sites as new healthcare dynamics continue to unfold every day.”
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
Investor Relations Contact: | Press/Media Contact: |
Ronnie Speight | Gary Gatyas |
Senior Vice President, Investor Relations | Executive Director, External Communications |
+1 919 745 2745 | +1 908 763 3428 |
Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com |
Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…
NEW YORK, July 9, 2024 /PRNewswire/ -- Scanning electrochemical microscopy (SECM) is used for imaging…
SAN DIEGO, July 9, 2024 /PRNewswire/ -- Puro Sound Labs, a leader in safe listening technology,…
NEW YORK, July 9, 2024 /PRNewswire/ -- Real-time Location Systems (RTLS) are technologies used to…
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO, July 9, 2024 /PRNewswire/ --…
U.S. health systems are increasingly embracing ambient documentation solutions to reduce providers' administrative workloads and…